Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 14/20 | 0.53 |
| ▸ | GCK | P35557 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16671048 | 0.85 | FGFR4 (0.55) | FGFR4 | |
| SCHEMBL16671196 | 0.83 | FGFR4 (0.60) | FGFR4 | |
| SCHEMBL16668744 | 0.76 | MCHR1 (0.42) | FGFR4GCK | |
| SCHEMBL16667982 | 0.76 | MCHR1 (0.42) | FGFR4GCK | |
| SCHEMBL16668433 | 0.74 | FGFR4 (0.38) | FGFR4GCKRARARARB | |
| SCHEMBL16668430 | 0.74 | FGFR4 (0.38) | FGFR4GCKRARARARB | |
| SCHEMBL16671033 | 0.74 | FGFR4 (0.60) | FGFR4 | |
| SCHEMBL16670856 | 0.73 | CNR2 (0.49) | FGFR4 | |
| SCHEMBL16671066 | 0.70 | XDH (0.41) | FGFR4ABL1 | |
| SCHEMBL32667306 | 0.70 | ABL1 (0.49) | GCKABL1RARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463653-B2 | Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-11-05 | — | — | US | disclosed |
| EP-3200786-B1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231760-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | EVERNOV MEDICINES LIMITED (CN) | 2019-08-01 | — | — | US | disclosed |
| US-20190076412-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | EVERNOV MEDICINES LIMITED (CN) | 2019-03-14 | — | — | US | disclosed |
| US-20180185341-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-07-05 | — | — | US | disclosed |
| EP-3060563-B1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9896449-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| EP-3200786-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-03-09 | — | — | US | disclosed |
| US-9533988-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-01-03 | — | — | US | disclosed |
| EP-3060563-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| WO-2016054483-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015059668-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185341-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | FGFR4 1/4885GCK 2107/4885ABL1 23/4885 |
| US-20190076412-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885GCK 2226/4885ABL1 22/4885 |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885GCK 1564/4885ABL1 33/4885 |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885GCK 1564/4885ABL1 33/4885 |
| US-20190231760-A1 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | FGFR4 1/4885GCK 2107/4885ABL1 23/4885 |
| US-10463653-B2 | Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885GCK 2226/4885ABL1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.